ABSTRACT: Cardio-oncology is an emerging discipline focused predominantly on the detection and management of cancer treatmentinduced cardiac dysfunction (cardiotoxicity), which predisposes to development of overt heart failure or coronary artery disease. The direct adverse consequences, as well as those secondary to anticancer therapeutics, extend beyond the heart, however, to affect the entire cardiovascular-skeletal muscle axis (ie, whole-organism cardiovascular toxicity). The global nature of impairment creates a strong rationale for treatment strategies that augment or preserve global cardiovascular reserve capacity. In noncancer clinical populations, exercise training is an established therapy to improve cardiovascular reserve capacity, leading to concomitant reductions in cardiovascular morbidity and its attendant symptoms. Here, we overview the tolerability and efficacy of exercise on cardiovascular toxicity in adult patients with cancer. We also propose a conceptual research framework to facilitate personalized risk assessment and the development of targeted exercise prescriptions to optimally prevent or manage cardiovascular toxicity after a cancer diagnosis.
during exposure to known cardiotoxic agents in highrisk patients (eg, anthracycline dose >200 mg/m 2 , HER2 therapy, or history of cardiovascular disease [CVD] ). 10 Despite the cardiac-centricity of current guidelines, therapy-induced direct and indirect (eg, deconditioning, unfavorable changes in body composition) consequences extend across the entire cardiovascular-skeletal muscle axis (ie, whole-organism cardiovascular toxicity). Cardiorespiratory fitness (CRF), an integrative assessment of global cardiovascular function, 11 declines between 5% and 26% during exposure to various systemic combinational regimens 12, 13 and may not recover after treatment cessation. 14, 15 Such impairments may predispose to excess noncancer competing morbidity and its attendant symptom burden (eg, poor quality of life, fatigue). 16 The global nature of cardiovascular toxicity portends the requirement for multifactorial treatment strategies with the capacity to augment or preserve whole-organism cardiovascular function. Structured exercise therapy (hereto referred to as exercise) is a central component of comprehensive rehabilitation among a wide number of cardiac and pulmonary conditions. 17 In contrast, neither cancer nor treatment with known cardiotoxic regimens is a qualifying condition for exercise rehabilitation in North America; therefore, exercise is not currently considered a standard aspect of cancer management. 18 Nevertheless, a growing body of work is emerging investigating the efficacy of exercise in cancer, a field known as exercise oncology. 19 Here, we overview the tolerability and efficacy of exercise on cardiovascular toxicity outcomes in adult patients with cancer. We also propose a conceptual research framework to facilitate personalized risk assessment and the development of targeted exercise prescriptions to optimally prevent or manage cardiovascular toxicity in cancer.
CURRENT EVIDENCE
We conducted a comprehensive review of definitive (phase III) clinical trials, observational cohorts, and smaller randomized controlled trials (RCTs) evaluating the association between exercise and subclinical (eg, CRF, CVD risk factors) or overt (eg, HF, CVD-related mortality) cardiovascular outcomes either during or after primary definitive therapy.
During Therapy
Phase III trials during definitive therapy (eg, chemotherapy, radiation) are not yet available. One observational cohort study from Palomo and colleagues 20 found that compared with <2.5 metabolic equivalent hours per week (MET-h·wk −1 ), ≈18 MET-h·wk −1 was associated with an adjusted 47% (95% confidence interval [CI] , 0.43-0.80) and 31% (95% CI, 0.46-1.04) lower risk of any CVD event and coronary artery disease death, respectively, in 4015 patients with primary breast cancer after a median follow-up of 12.7 years. 20 There is a paucity of RCT data investigating the efficacy of exercise on subclinical (eg, CRF, CVD risk factors) cardiovascular outcomes in this setting. Nevertheless, at least 11 trials have examined the efficacy of various exercise prescriptions on CRF (Table 1 ). In the first pioneering study, MacVicar et al 21 assessed the efficacy of 10 weeks of supervised standard prescription (ie, a prescription that maintains a fixed intensity, frequency, and duration throughout the intervention after an initial lead-in period) of interval training (3 d/wk; intensity between 60% and 85% heart rate reserve), supervised stretching, or usual care on peak oxygen consumption (Vo 2 peak) in 45 patients with primary breast cancer initiating various chemotherapy regimens. Compared with nonexercise groups, aerobic training led to a mean Vo 2 peak improvement of 40%. 21 The next trial was not published until more than a decade later, when Segal et al 22 compared the efficacy of a 26-week home-based or supervised standard aerobic prescription (3 to 5 d/wk, session duration not reported, at 50% to 60% of estimated Vo 2 peak) and usual care in patients with primary breast cancer initiating various therapy regimens (66% received anthracycline-based regimens). No significant changes in CRF were observed in any group. 22 Additional trials have investigated the effects of exercise on CRF in breast cancer receiving contemporary adjuvant chemotherapy. 23, 27, 28 For instance, van Waart et al 28 randomized 230 patients with primary breast cancer to standard home-based low-intensity (5 d/wk, 30 minutes a session at 12-14 on Borg scale), the combination of aerobic and resistance training (5 d/wk; 2 supervised combined exercise, 3 home-based aerobic exercise, 30 minutes of aerobic exercise at 12-16 rated perceived exertion and 20 minutes of resistance training), or usual care control. From baseline to after the intervention (12 weeks), CRF declined ≈17% in usual care, a decline significantly attenuated in the home-based group only (although a decline of ≈9% was still observed). 28 In a randomized pilot trial, our group investigated the efficacy of nonlinear aerobic training prescription (ie, intensity and duration of the exercise stimulus continually altered across the entire study period) in 20 patients with locally advanced breast cancer initiating neoadjuvant anthracycline-cyclophosphamide chemotherapy. 27 After 12 weeks, Vo 2 peak decreased by 1.5±2.2 mL·kg ·min −1 (13%) in the anthracycline-cyclophosphamide plus aerobic training group. 27 Finally, in a study evaluating nonlinear aerobic exercise (3 d/wk, 15-45 minutes a session at 55% to 80% Vo 2 peak) or attention control (stretching) in 65 women with metastatic (stage IV) breast cancer (57% receiving chemotherapy; >40% with ≥2 lines of Scott et al Personalization of Exercise Therapy in Cancer prior therapy), on the basis of predefined criteria (ie, attendance >70%), supervised aerobic exercise at the dose and schedule tested was safe (no serious adverse events) but not tolerated in all patients (mean attendance, 63%); exercise was associated with significant improvements in Vo 2 peak among patients with exercise tolerability. 28a Beyond breast cancer, Segal and colleagues 25 compared the efficacy of 3 d/wk of resistance (60%-70% 1-repetition maximum) or aerobic training (15-45 minutes per session, 50%-75% Vo 2 peak) following a standard prescription approach versus usual care in 121 patients initiating radiotherapy with or without receiving androgen deprivation therapy for early or locally advanced prostate cancer. After 24 weeks, both exercise groups abrogated the ≈5% significant decline observed in the usual care group. Courneya et al 24 evaluated the efficacy of nonlinear aerobic exercise (3 d/wk, 15-45 minutes per session at 60%-100% Vo 2 peak) in 122 patients with Hodgkin or non-Hodgkin lymphoma during (n=54, 44%) or after (n=68, 56%) chemotherapy or radiation therapy. After 12 weeks, mean Vo 2 peak increased by 4.6 mL·kg −1 ·min −1 (≈17%) compared with a mean decrease of 0.6 mL·kg −1 ·min −1 (≈2%) in usual care. There was no interaction between treatment status and Vo 2 peak response to aerobic training (P=0.40).
Only 1 RCT, to the best of our knowledge, has investigated the effects of exercise on cardiovascular outcomes other than CRF. Jones et al 27 (described in During Therapy above) found that increases in Vo 2 peak occurred in con- , 4%). Anemia is associated with LV dilation 30 and was an independent risk factor for CVD in 14 410 subjects without CVD. All interventions were described according to the classic components of exercise prescription: type (modality), program length (total number of training weeks), Fq (mean number of exercise sessions a week), duration (duration spent on 1 session of exercise), and intensity (percentage of a predetermined physiological parameter such as maximum HR obtained from baseline cardiopulmonary exercise test). All outcomes were described according to LTF (number of patients who dropped out divided by total number of patients), safety (number of AEs), attendance (number of exercise sessions attended divided by the total number of planned sessions), adherence (number of exercise sessions that were completed at the planned duration and intensity divided by the number of planned sessions attended), and efficacy (change in outcome).
ADT indicates androgen deprivation therapy; AE, adverse event; AT, aerobic training; CE, cycle ergometer; CT, combined aerobic and resistance training; CVD, cardiovascular disease; ET, elliptical trainer; FMD, flow-mediated dilatation; Fq, frequency; HPL, hyperlipidemia; HR, heart rate; HRR, heart rate reserve; HTN, hypertension; LTF, loss to follow-up rate; NR, not reported; RCT, randomized controlled trial; RDI, relative dose intensity (ratio of total completed to total planned cumulative dose); reps, repetitions; RM, repetition maximum; RT, resistance training; TM, treadmill; UC, usual care; and Vo 2 peak, peak oxygen consumption.
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In summary, short-term (12-26 weeks) anticancer therapy causes marked and significant impairments in CRF (up to 26%) compared with a typical 10% decline every decade in normal aging, 32 indicating an "accelerated cardiovascular aging" phenotype. 12 Although the molecular mechanisms are incompletely understood, recent elegant work demonstrated that anthracycline-containing chemotherapy increased the expression of the cellular senescence marker p16
INK4a by almost 1 log 2 order of magnitude immediately after chemotherapy, and it remained elevated for up to 12 months after treatment in patients with primary breast cancer 33 ; the magnitude of increase corresponded to 14.7 years of chronological aging. 33 In this context, whether exercise completely abrogates the cancer treatment-induced decline in CRF remains unclear. The available mixed findings may be attributable to the differences in adjuvant therapy regimens (eg, taxane, 26 non-taxane-based therapy, 34 androgen deprivation therapy 25 ), baseline profile of patients (eg, inclusion 29 or exclusion 25, 28 of patients with preexisting CVD risk factors), prescription approach (ie, standard 26 versus nonlinear 34 ), or intensity (ie, moderate intensity only 33 versus prescriptions incorporating higher-intensity exercise 29, 34 ). In addition, despite the general consensus that exercise is safe and tolerable for patients with cancer, 35, 36 few studies systematically monitored or reported these end points. 
After Therapy
Data from phase III trials are not currently available. In observational evidence, after a median follow-up of 10 years, compared with <3 MET-h·wk
was associated with a 19% (P=0.026), 39% (P=0.026), and 11% (P=0.17) reduction in all-cause, recurrence/ progression, and health-related deaths, respectively, in 15 450 adult survivors of childhood cancer. 28a In addition, an increase in exercise exposure (7.9±4.4 MET-h/ wk) over an 8-year period was associated with a 40% reduction in all-cause mortality rate compared with maintenance of low exercise exposure (rate ratio, 0.60; 95% CI, 0.44-0.82, P=0.01). In related work, increasing exercise exposure was associated with a strong, graded reduction in the risk of CVD events and CVD mortality in AT: ↑0.5% UC: no change Significant between-group difference All interventions were described according to the classic components of exercise prescription: type (modality), program length (total number of training weeks), Fq (mean number of exercise sessions a week), duration (duration spent on 1 session of exercise), and intensity (percentage of a predetermined physiological parameter such as maximum HR obtained from baseline cardiopulmonary exercise test). All outcomes were described according to LTF (number of patients who dropped out divided by total number of patients), safety (number of serious AEs), attendance (number of exercise sessions attended divided by the total number of planned sessions), adherence (number of exercise sessions that were completed at the planned duration and intensity divided by the number of planned sessions attended), and efficacy (change in outcome).
AE indicates adverse event; AT, aerobic training; CE, cycle ergometer; CT, combined aerobic and resistance training; CRF, cardiorespiratory fitness; CVD, cardiovascular disease; ET, elliptical trainer; FMD, flow-mediated dilatation; Fq; frequency; HF, heart failure; HPL, hyperlipidemia; HR, heart rate; HRR, heart rate reserve; HTN, hypertension; LTF, loss to follow-up rate; NR, not reported; RCT, randomized controlled trial; TM, treadmill; UC, usual care; and Vo 2 peak, peak oxygen consumption.
2973 women with primary breast cancer 37 ; adherence to exercise guidelines was associated with a 23% reduction in CVD events. 37 Similar to during therapy, few studies have investigated the effects of exercise on subclinical cardiovascular outcomes in this setting, with most data available on CRF (Table 2 Few studies have assessed the effects of exercise on cardiovascular end points beyond CRF. Adams and colleagues 44 reported that compared with usual care, 12 weeks of high-intensity interval aerobic training (3 d/wk, 35-minute session at 75%-95% Vo 2 peak) improved Vo 2 peak (adjusted mean group difference, 3.7 mL·kg
), vascular function (adjusted mean group differences, −0.6 mm, 1.54 10 −3 /kPa, and −2.02 m/s for carotid intima-media thickness, carotid distensibility, and arterial stiffness, respectively), and Framingham risk score (adjusted mean group difference, −0.6%) in 63 patients with testicular cancer. Two RCTs specifically recruited patients at high risk of or with overt CVD. In an RCT by Jones et al, 42 a protocol-defined eligibility criterion was a Vo 2 peak below age-and sex-matched normative sedentary norms in men with prostate cancer. Nonlinear aerobic training (5 d/wk [3 days supervised, 2 days home-based training], 30-60 minutes a session at 55%-100% of measured Vo 2 peak for 24 weeks) increased Vo 2 peak in conjunction with improvements in endothelial function but no changes in other CVD markers (eg, lipid profile, blood pressure, body composition). 42 The same investigators conducted an unplanned, ancillary retrospective analysis of 90 patients enrolled in the HF-ACTION trial (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) 45 with a history of cancer. 41 Intention-to-treat analyses indicated no differences in the primary end point (all-cause mortality or hospitalization) after a median follow-up of 35 months (hazard ratio, 1.11; 95% CI, 0.69-1.77). 41 For secondary end points, the incidence of cardiovascular mortality or cardiovascular hospitalization was significantly higher in the exercise group compared with the usual care group (67% versus 41%; hazard ratio, 1.94; 95% CI, 1.12-3.16), whereas no significant differences in Vo 2 peak were observed in either group. 41 In sum, there is reasonable evidence to support the conclusion that exercise improves CRF after the completion of cancer therapy, although several studies found no effects of exercise. 39, 41, 43 The discrepant findings may be due to methodological differences or possibly differences in the long-term, persistent effects of certain anticancer therapies. There is insufficient evidence to conclude that exercise improves other markers of cardiovascular health in this setting.
Summary of Current Evidence
As reviewed here, the efficacy and mechanisms of exercise to prevent or mitigate cardiovascular toxicity after a cancer diagnosis are limited. Moreover, beyond observational studies, investigation of exercise is limited primarily to CRF, an end point of significant clinical importance because poor CRF is associated with a higher prevalence of acute and chronic treatment-related toxicities (eg, CVD), 15, [46] [47] [48] [49] higher symptom burden (eg, fatigue), [50] [51] [52] and increased risk of all-cause and cancerspecific mortality in patients with cancer.
14,53,54 Nevertheless, CRF is not a traditional CVD risk factor, nor is it a component of ideal cardiovascular health score. 55 Against this background, current and exploratory exercise-oncology paradigms are presented in the following section.
PERSONALIZED EXERCISE-ONCOLOGY RESEARCH Current Paradigm
Precision or high-definition medicine, understanding the mechanisms or predictors of disease risk or treatment response in an individual patient or phenogroup of patients to guide tailored treatment strategies, is becoming the paradigm in clinical investigation. 56 In stark contrast, investigation of exercise as a therapeutic strategy in chronic disease has not yet adopted such an approach. Instead, the traditional approach has been to test the efficacy of standard prescriptions that closely adhere to the national exercise guidelines (ie, aerobic alone, resistance alone, or the combination 3-5 d/wk, 20-60 minutes a session at 55%-75% of age-predicted or measured heart rate maximum or reserve or 12-24 weeks). Although this approach has an aspect of personalization (exercise dosing intensity is targeted to each individual patient on the basis of measured or predicted heart rate), the dose (ie, modality, frequency [per week], duration [per session], intensity [per session], and length of treatment exposure) and the scheduling (linear prescription) are similar both within and across major disease conditions. Thus, the current paradigm operates under the overarching assumption that all patients respond equally to a standard exercise dose ("one size fits all").
Clearly, despite this, it could be argued that relatively homogeneous exercise prescriptions have consistently been shown to improve a diverse range of end points largely regardless of disease condition and setting, therefore questioning the rationale to investigate targeted approaches. However, the vast majority of observational and RCT studies and related metaanalyses/systematic reviews 36, 57 focus on the overall treatment effect for the entire study sample. Accordingly, presentation of the mean result masks the variability in responses (ie, those with lesser or greater benefit than the overall population) that could be observed within a heterogeneous population. 58 Emerging data from several ancillary analyses indicate that there is considerable heterogeneity in exercise response even for changes in CRF. For instance, in the HF-ACTION trial, despite a mean increase in Vo 2 peak of 0.6 mL·kg −1 ·min −1 (4%) after 12 weeks of aerobic training, change in Vo 2 peak ranged from −12 (−83%) to 14 mL·kg −1 ·min −1 (97%). 59 Moreover, only ≈50% of patients randomized to exercise experienced a Vo-2 peak change ≥1.0 mL·kg −1 ·min −1 , a change considered clinically important. 60 In the oncology setting, we found that the mean change in Vo 2 peak after 24 weeks of aerobic training in patients with prostate cancer was ≈9%; patient-level data, however, revealed the Δ in Vo 2 peak ranged from −18% to 32%. 42 A similar response variability has been observed in other cardiovascular end points. Leon et al 61 reported a significant 4% group mean increase in high-density lipoprotein cholesterol; however, the individual patient change ranged from −24% to 66% in 675 sedentary subjects after 20 weeks of standard aerobic training (3 d/wk, 30-50 minutes at 55%-75% Vo-2 peak). A threshold effect (ie, prescribed exercise dosing intensity is insufficient to confer meaningful cardiovascular adaptation) has been proposed to explain low responders to exercise. 62, 63 Ross and colleagues 62 examined this hypothesis in an ancillary analysis of standard aerobic training in sedentary obese adults. Results indicated that either higher exercise intensity or volume decreased the number of low responders as defined by improvements in CRF. Nevertheless, increasing exercise intensity or volume is unlikely to be an all-encompassing solution to improve exercise response variability and may even be contraindicated in certain clinical populations. 41 In addition to heterogeneity in a specific end point (eg, CRF), there appears to be heterogeneity across study end points within a specific study cohort. For instance, Kraus et al 64 found that improvements in CRF were similar for high-duration, high-intensity (≈20 miles/wk at 65%-80% of Vo 2 peak) and low-duration, high-intensity (≈12 miles/wk at 65%-80% of Vo 2 peak) training, yet improvements in lipoprotein profile were superior with high-duration, high-intensity exercise among 84 overweight men and women with mild to moderate dyslipidemia. Similarly, Ross and colleagues 65 found that a standard aerobic training prescription was associated with substantial reductions in abdominal obesity, whereas improvements in CRF and 2-hour glucose levels were confined to high-dose exercise among 300 abdominally obese adults. These data indicate that the same exercise prescription confers differential effects across different end points, supporting the notion that exercise should be designed to target the primary end point of interest. This is consistent with the principle of specificity: The selected exercise stress must be specific and targeted to the primary underlying system(s) or pathway(s) known or postulated to underpin the primary end point of interest. 66 Finally, in addition to exercise response heterogeneity in efficacy end points, it is important to consider variability in exercise safety and tolerability. Even within a seemingly homogeneous cohort (eg, primary breast cancer), there may be considerable variability in treatment (eg, radiation, chemotherapy), CVD risk factors (eg, age, hypertension, dyslipidemia), and baseline physiological status (eg, below or comparable to age-and sex-matched Vo 2 peak). 64 Depending on the patient's baseline status (and therefore inherent capacity to respond to external physiological stress in the form of exercise), a standard exercise prescription dose may be insufficient (undertraining), sufficient (physiological adaptation), or excessive (overtraining). Such a consideration may be especially important in patients with cancer given the potential of anticancer therapies to alter the exercise-adaptation relationship. 66 As outlined above, supervised aerobic exercise was not tolerated in all patients with metastatic breast cancer 28a , whereas the incidence of cardiovascular mortality or cardiovascular hospitalization was significantly higher in patients with HF with a history of cancer randomized to aerobic exercise compared with control. 41 These findings provide initial evidence to suggest that a subgroup of patients with cancer could be too ill to adhere to a prescribed exercise dose or may even experience an adverse exercise response.
Collectively, the above examples create a strong rationale for the development and testing of alternative tailored approaches to optimize the efficacy, tolerability, and safety of exercise in the oncology setting (Figure 1 ).
Exploratory Paradigms
The development of targeted exercise prescriptions requires an initial evaluation (ie, phenotyping) of clinical
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and/or medical parameters that permits stratification of patients with a common but heterogeneous condition into homogeneous subgroups (ie, phenogroups). 56 In this context, we overview below 3 potential screening/ evaluation (phenogrouping) approaches that could be applied to research investigations designed to assess the efficacy of exercise on cardiovascular toxicity in the oncology setting (Figure 2 ). These screening approaches range from methods that leverage existing risk stratification models to increasingly multifaceted approaches that incorporate more detailed physiological and potentially biological phenotyping. We further speculate on how these approaches might facilitate the design of phenogroup-targeted exercise prescriptions and illustrate how more detailed phenotyping may permit the design of even more targeted/personalized prescriptions. Given the preliminary nature of this paradigm and approach, we explore the application of these tenets to the investigation of exercise on CRF. We selected CRF because the majority of exercise-oncology research to date has used this outcome and because CRF is a strong predictor of lateoccurring CVD.
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Approach 1: Model/Guideline-Based Risk Stratification
Screening The extent of patient evaluation and pre-exercise screening in the majority of exercise-oncology studies is physician/oncologist clearance, whereas stratification is typically confined to type of diagnosis (eg, breast, prostate) or setting (eg, during, after therapy) rather than cardiovascular toxicity risk profile. Although a decline in CRF and impaired CRF 14, 16 appear to be cardinal features after a cancer diagnosis, predictors of individual risk of CRF decline are not known. 67 Therefore, a logical and practical first step in studies designed to prevent or mitigate cardiovascular toxicity is the selection of patients on the basis of late cardiovascular toxicity risk. Several models accurately predict individual patient risk of late-occurring CVD after a cancer diagnosis and assist in the stratification of patients into low-, moderate-, and high-risk groups on the basis of widely available clinical information such as sex and radiation/chemotherapy exposures. 68 For instance, the American Society of Clinical Oncology guidelines 10 have identified patient subgroups considered at high risk of LV dysfunction or HF (Table 3) . 10 Unfortunately, available risk stratification models provide limited information with which to design targeted exercise prescriptions, but they identify those at highest risk of future events for prophylactic intervention.
Targeted Exercise Prescription
The optimal exercise dose to prevent CVD events and mortality is not known; however, exercise recommendations from the Centers for Disease Control and Prevention 69 and the American Heart Association 70 (ie, 3 d/wk, 30-60 minutes a session at 70%-80% of peak heart rate determined from a symptom-limited exercise stress test) affirm the primary role of exercise in preventing chronic disease. The clinical applicability of generic exercise guidelines (which are identical to current national and international exercise guidelines for patients with cancer 71 ) is high; however, as outlined above, precision for the individual patient is low. Current practice (left) stratifies patients on the basis of tumor type and provides a generic exercise prescription (typically based on predicted maximum heart rate), resulting in a heterogeneous response. Nextgeneration practice (right) stratifies patients on the basis of multiple factors and provides a targeted exercise prescription based on phenogroup, resulting in optimized efficacy, safety, and tolerability of exercise therapy. Rx indicates prescription.
Approach 2: Model/Guideline-Based Risk Stratification Plus Exercise Stress Testing
Screening Incorporation of data from exercise stress testing (in conjunction with available risk models overviewed in approach 1) may further facilitate risk stratification. Exercise stress tests can identify contraindications (eg, hypertension, ischemia) and exertional symptoms, provide an objective determination of CRF, and guide targeted interventions. 70 International guidelines on the proper conduct of a range of submaximal and maximal exercise stress testing are available. 72 For instance, with minimal instrumentation and trained personnel requirements, functional testing (eg, 6-minute walk test) and submaximal exercise testing (eg, submaximal work rates) are viable options in markedly deconditioned patients and can be performed with minimal risk to patients. 11 Maximal stress testing with electrocardiographic monitoring can also be used to estimate CRF, 11 and measured peak heart rate can be used to facilitate prescription design. 11 Finally, cardiopulmonary exercise tests with measurement of ventilatory gas exchange may be the preferable method because they can provide an objective assessment of submaximal and Vo 2 peak and delineation of the pathophysiological mechanisms underlying exercise limitations. 72 Vo 2 peak is determined by a series of steps that transport oxygen from the environment to the skeletal muscle mitochondria, also known as the oxygen pathway. 67 As a result, additional patient stratification could occur through assessment of any defective step(s) along the oxygen pathway via (1) cardiopulmonary exercise tests with gas exchange to determine Vo 2 peak, (2) cardiac output assessed noninvasively (eg, echocardiography) 73 or invasively (eg, intracardiac hemodynamic data from a pulmonary artery), 74 (3) blood hemoglobin concentration, and (4) arterial-venous oxygen content difference assessed noninvasively (eg, calculated from the Fick equation) 72 or invasively (eg, arterial blood gas data from a radial catheter). 75 To date, few studies have directly investigated the mechanisms of reduced CRF in patients with cancer. 67 Nevertheless, important insights can be gleaned from other clinical settings that have assessed determinants of poor CRF. 75 For example, Houstis and colleagues 75 quantified oxygen pathway deficiencies with invasive monitoring among 134 patients with HF and found that 2 of the steps, cardiac output and skeletal muscle oxygen diffusion, were impaired in a subgroup of patients by an average of 27±3% and 36±2%, respectively. Thus, identification of a subgroup of patients with shared defects could be used not only to stratify patients but also, as outlined below, to tailor therapy. Three example screening/exercise prescription approaches that could be applied to research investigations designed to assess the efficacy of exercise on cardiovascular toxicity in the oncology setting: (1) guideline-based approach (bottom row) applies American Society of Clinical Oncology (ASCO) cardiotoxicity guidelines and standard exercise guidelines; (2) ASCO guidelines and peak oxygen consumption (Vo 2 peak)-based approach (middle row) applies the addition cardiorespiratory exercise test (CPET) for risk stratification and exercise prescription design; and (3) the multidimensional data approach (top row) applies advanced analytics for both risk stratification and targeted exercise prescription design.
Targeted Exercise Prescriptions
Functional and submaximal exercise testing heart rate and blood pressure responses can be used to estimate peak values and to prescribe different exercise intensities for each patient that are independent of disease severity or baseline fitness. 76 Exercise prescriptions that are based on estimated baseline physiological end points have high clinical applicability but increase the susceptibility for underdosing or overdosing of exercise therapy. For instance, the use of age-predicted maximum heart rate may result in overtraining in patients with primary breast cancer treated with polychemotherapy caused by the resulting autonomic dysfunction and decreased heart rate reserve. 77 Therefore, the use of cardiopulmonary exercise test-based metabolic or ventilatory responses to generate 3 to 5 unique exercise intensity zones increases personalization and allows the specificity of exercise prescriptions. 42, 66 For example, high-intensity interval exercise sessions (eg, 6 times for 2 minutes above ventilatory threshold) activate mitochondrial biogenesis within skeletal muscle 78 and may be more effective for augmenting CRF. Finally, exercise prescriptions based on oxygen pathway defects could be implemented. In the case of CRF when the primary limitation is identified as a peripheral limitation (eg, decreased arterial-venous oxygen content difference resulting from decreased capillary density or impaired oxygen utilization by the exercising skeletal muscles), as could occur in sarcopenia or cachexia, whole-body exercise may not be the most effective mode of exercise to increase Vo 2 peak. Among cachexic patients with HF, Esposito et al 79 demonstrated that 2 months of 1-leg knee extensor exercise resulted in a significant increase in Vo 2 peak as a result of improvements in arterial-venous oxygen content difference.
Approach 3: Multidimensional Data-Based Risk Stratification
Screening Addressing the heterogeneity of patients with cancer on the basis of multiple medical (eg, cancer therapy, comorbidities, performance status) and physiological (eg, lipids, glucose, cardiopulmonary exercise test variables, cardiac function) characteristics could enable novel subgroup risk classifications. 58 Such integration of multidimensional data with machine learning, an approach that integrates statistical relationships and computer algorithms, 80 has been applied to combine complex data sets to cluster patients with HF into distinct, mutually exclusive groups. 81, 82 For example, using unsupervised learning (ie, identifying subgroups without a predicted outcome) in an ancillary analysis of the HF-ACTION trial, Ahmad and colleagues 82 identified 4 novel subgroups that varied in baseline clinical characteristics (eg, age, sex, race, symptoms, comorbidities, biomarkers), response to aerobic exercise, and incidence of cardiovascular death and/or cardiovascular hospitalization. Similarly, using 67 candidate variables (eg, echocardiography, ECG-based data points), Shah and colleagues 81 identified 3 mutually exclusive subgroups in a cohort of 397 patients with HF. Whether machine learning could be applied to identify subgroups of patients with cancer at high risk of cardiovascular toxicity is unknown, but previous studies in oncology and cardiology indicate that it is a promising avenue for future work.
Targeted Exercise Prescriptions
Classifying patients a priori into distinct subgroups based on multidimensional data to guide the design of exercise prescriptions undoubtedly represents a significant challenge. 83 However, a landmark framework by Zeevi and colleagues 84 provided proof of concept that applying deep clinical phenotyping in conjunction with machine-based learning enabled the design of an effective personalized nutrition intervention. To exemplify the potential application of multidimensional data and machine learning to guide exercise prescription design, the following steps could be applied in a cohort of patients with breast cancer who had completed a 12-week exercise program with CRF as the primary end point ( Figure 3) . First, patients would be extensively characterized with multidimensional data (eg, treatment, medical, physiological). Second, unsupervised learning would be applied to develop a parsimonious number of subgroups (with internal validation). Third, an independent validation analysis in a separate cohort using the same multidimensional data would be performed. Finally, supervised learning within each subgroup would be applied to ascertain predictors of CRF. Once subgroup-specific predictors of CRF were identified, the next logical step would be to design and test personalized exercise prescriptions that are specifically targeted to CRF predictors in a de novo breast cancer cohort. This approach is consistent with the precision medicine initiative to assess individual variability and personalize prevention and treatment strategies, 56 but it has not yet been tested in any exercise setting.
CHALLENGES AND FUTURE DIRECTIONS OF PERSONALIZED EXERCISE THERAPY
Many critical questions pertaining to the implementation of precision medicine have been outlined previously. 56, 83 Here, we briefly discuss major barriers germane to personalized exercise therapy to optimize CRF. Addressing these and other challenges is not only scientifically intriguing but also critical to inform policy, evidence-based guidelines, and daily clinical care.
Screening
A fundamental step is to discern what factors should be included in risk screening. Unlike identification of therapy-related factors predictive of LV dysfunction or HF, 10 factors predictive of CRF decline and CRF response to exercise in patients with cancer are unknown. Accordingly, characterization of deficits in the oxygen pathway is arguably the first knowledge gap that needs to be addressed. Investigation of whether incorporation of additional biomarkers (eg, troponins 85 ) or 'omics (eg, genomics 86 ) improves risk stratification is needed. For example, results from a genome-wide association study in survivors of childhood cancer suggest that there is a modifying effect of a polymorphism of CELF4 on anthracycline dose-dependent HF risk. 87 Whether this polymorphism is associated with CRF decline is unknown. Similarly, ≈200 genetic variants have been associated with physical performance to date 86 ; however, even in genome-wide association studies, the physiological and clinical significance of genetic predictors is low. 88 Finally, risk stratification will become increasingly complex with multidimensional screening factors, and there will be a need for advanced analytical approaches to aid in the development of parsimonious subgroups. Nevertheless, advanced analytical solutions are emerging in other areas of medicine 89 that could be applied to exercise oncology research.
Targeted Exercise Prescriptions
The approach of personalizing interventions by first categorizing patients into more homogeneous subgroups to then deliver targeted therapy has been in practice in oncology for >40 years. 90 Application of this model to exercise oncology will clearly represent a paradigm shift for both patients and researchers and require a novel framework. Phase I/II trials that evaluate exercise safety and tolerability may be a prerequisite for initiating clinical exercise trials, whereas rigorous clinical trials conducted in a highly structured, clinical-based setting with all ses- sions monitored and supervised by certified exercise professionals may be necessary to demonstrate the efficacy of a novel exercise training paradigm. In theory, different training modalities and different doses and lengths of training programs will be indicated. Such personalized dosing has been successfully tested in several clinical research settings. In a pilot RCT, Zarrinpar and colleagues 91 used multidimensional patient phenotyping and machine learning to develop personalized dosing of tacrolimus to prevent underdosing and overdosing among patients receiving liver transplants. These research approaches that integrate multiple fields (eg, exercise, oncology, cardiology, computational medicine) will be essential to test and implement targeted exercise prescriptions.
Implementation
Transition from research settings to widespread clinical applicability represents a significant challenge. Delivery of personalized exercise therapy could consist of several different supervised, unsupervised, or hybrid clinic/community/home-based models. In certain settings, application of a cardiac rehabilitation model to the oncology setting could allow patients access to structured exercise interventions across the cancer continuum. For instance, given the emergent data on the prognostic importance of presurgical CRF on postsurgical outcomes, 48, 49, 54 the introduction of exercise therapy to improve CRF in the interval between diagnosis and cancer interventions may have considerable clinical benefit. 92 The American Association of Cardiovascular and Pulmonary Rehabilitation guidelines outline a continuum of services ranging from inpatient programs (during hospitalization) to transitional programs (during postacute care), outpatient programs (6 weeks after hospital discharge and continuing for up to 12 weeks), and long-term maintenance programs (after completion of outpatient programs). 93 An alternative community-based model is the LIVESTRONG at the YMCA exercise program. 94 This 12-week, supervised, group-based program for patients with a history of cancer is currently offered in ≈20% of YMCA branches across the United States. 94 Finally, widespread implementation of home-based tele-exercise programs with monitoring 95 could ensure the safety and efficacy of exercise programs with lower patient burden.
CONCLUSIONS
Cardiovascular toxicity is a devastating adverse consequence of cancer therapy for numerous patients, especially those living 5 years beyond initial diagnosis. 96 In certain cancer populations with primary disease, CVD mortality not only is more common (2-to 4-fold higher) but also occurs at an earlier age than in the general population. 96 With ≈16.7 million adults living with a history of cancer in the United States, a figure expected to reach ≈26 million by 2040, 97 cardiovascular medicine specialists can expect or are already managing a large proportion of patients with cancer with or at high risk of cardiovascular toxicity. Although the current evidence base is limited, the demonstrated benefit and centricity of exercise in other clinical populations suggest that it may also become a key feature of future programs in the oncology setting. In the design of such programs, the adoption and implementation of a targeted/precision medicine approach could be critical to optimize the efficacy, safety, and tolerability of exercise for patients with a history of cancer. 
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